These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19073820)

  • 1. Modern treatment of amyloidosis: unresolved questions.
    Dember LM
    J Am Soc Nephrol; 2009 Mar; 20(3):469-72. PubMed ID: 19073820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of amyloidosis].
    Wien TN
    Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1397-400. PubMed ID: 18552901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary amyloidosis of the kidney.
    Shafique S; Wetmore J; Almehmi A
    W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis.
    Sack FU; Kristen A; Goldschmidt H; Schnabel PA; Dengler T; Koch A; Karck M
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):257-62. PubMed ID: 18096396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
    Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
    Amyloid; 2009 Dec; 16(4):243-5. PubMed ID: 19922338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloidosis-associated kidney disease.
    Dember LM
    J Am Soc Nephrol; 2006 Dec; 17(12):3458-71. PubMed ID: 17093068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment in systemic amyloidosis].
    Ikeda S
    Rinsho Byori; 2008 Feb; 56(2):121-9. PubMed ID: 18404826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
    Breems DA; Sonneveld P; de Man RA; Leebeek FW
    Eur J Haematol; 2004 Mar; 72(3):181-5. PubMed ID: 14962236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in diagnosis and treatment of AL amyloidosis].
    Zelichowski G; Lubas A; Wańkowicz Z
    Pol Merkur Lekarski; 2008 Apr; 24(142):340-5. PubMed ID: 18634370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AL amyloidosis manifesting as systemic lymphadenopathy.
    Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
    Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histological responses of renal amyloidosis to high-dose melphalan supported by autologous stem cell transplantation.
    Sanada S; Suzuki M; Shindo T; Suzuki S; Nakamichi T; Matsubara M; Maeda K
    Nephrol Dial Transplant; 2008 Feb; 23(2):747-50. PubMed ID: 17989105
    [No Abstract]   [Full Text] [Related]  

  • 19. Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant.
    Muzaffar J; Katragadda L; Haider S; Abdallah AO; Anaissie E; Usmani SZ
    Acta Haematol; 2013; 130(3):146-9. PubMed ID: 23689541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report.
    Gertz MA; Lacy MQ; Dispenzieri A
    Bone Marrow Transplant; 2000 Mar; 25(5):465-70. PubMed ID: 10713619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.